J
Jeffrey L. Winters
Researcher at Mayo Clinic
Publications - 189
Citations - 12616
Jeffrey L. Winters is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Apheresis & Transplantation. The author has an hindex of 47, co-authored 178 publications receiving 10662 citations. Previous affiliations of Jeffrey L. Winters include New York University & University of Virginia.
Papers
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Evan M. Bloch,Shmuel Shoham,Arturo Casadevall,Bruce S. Sachais,Beth H. Shaz,Jeffrey L. Winters,Camille M. van Buskirk,Brenda J. Grossman,Michael J. Joyner,Jeffrey P. Henderson,Andrew Pekosz,Bryan Lau,Amy Wesolowski,Louis M. Katz,Hua Shan,Paul G. Auwaerter,David L. Thomas,David J. Sullivan,Nigel Paneth,Eric A. Gehrie,Steven L. Spitalnik,Eldad A. Hod,Lewis Pollack,Wayne T. Nicholson,Liise Anne Pirofski,Jeffrey A. Bailey,Aaron A.R. Tobian +26 more
TL;DR: An overview of convalescent plasma is provided, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria.
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TL;DR: The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.
Journal ArticleDOI
Transfusion-related acute lung injury: Incidence and risk factors
Pearl Toy,Ognjen Gajic,Peter Bacchetti,Mark R. Looney,Michael A. Gropper,Rolf D. Hubmayr,Clifford A. Lowell,Philip J. Norris,Philip J. Norris,Edward L. Murphy,Edward L. Murphy,Richard B. Weiskopf,Gregory A. Wilson,Monique Koenigsberg,Deanna C. Lee,Randy M. Schuller,Ping Wu,Barbara Grimes,Manish J. Gandhi,Jeffrey L. Winters,David C. Mair,Nora V. Hirschler,Nora V. Hirschler,Rosa Sanchez Rosen,Rosa Sanchez Rosen,Michael A. Matthay +25 more
TL;DR: The identified risk factors provide potential targets for reducing residual TRALI and little or no risk was associated with older red blood cell units, noncognate or weak cognate class II antibody, or class I antibody.